12:00 AM
 | 
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

G3139: Phase I/II data; Phase III

Updated 1 year follow-up data from GNTA’s Phase I/II trial of G3139 plus Bayer AG’s DTIC-Dome dacarbazine chemotherapeutic showed anti-tumor responses...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >